Report Description Table of Contents Chagas Disease Treatment Market Market Size, Treatment Landscape, Pipeline, Regional Commercialization, and Competitive Outlook, 2026-2032 Scope and methodology: Strategic Market Research defines this market as revenue from etiological antiparasitic medicines for Trypanosoma cruzi infection plus pharmaceutical treatment attributable to Chagas-related cardiac, digestive, and neurological complications. Diagnostic tests, vector-control products, surgery, transplantation, pacemakers, implantable cardioverter-defibrillators, and clinical monitoring fees are excluded from direct market revenue. Market size, segment shares, and CAGRs are Strategic Market Research estimates; epidemiology, clinical practice, pipeline status, access programs, and company activity are validated against primary or authoritative sources current through August 2026. What Is the Chagas Disease Treatment Market Size and What Will Drive Growth Through 2032? The Global Chagas Disease Treatment Market was valued at USD 520 million in 2025 and is projected to reach USD 890 million by 2032, expanding at a CAGR of 8.0% during 2026-2032. The implied CAGR from the stated base and forecast values is 7.98%, confirming internal consistency. The central market issue is not expansion of the infected population; it is conversion of a very large hidden patient pool into diagnosed, treatment-eligible cases. The Chagas Disease Treatment Market focuses on medicines used to treat Trypanosoma cruzi infection and manage complications caused by chronic Chagas disease. Antiparasitic drugs such as benznidazole and nifurtimox are used to eliminate or suppress the parasite, particularly during the acute phase and in selected chronic patients. Treatment may also include medicines for Chagas-related cardiac, digestive, and neurological complications. The World Health Organization estimated in April 2026 that about 8 million people are infected with T. cruzi worldwide, more than 10,000 die each year, and more than 100 million are at risk. Cases have been identified in 44 countries, while congenital transmission now accounts for more than 10,000 new infections annually at global level. DNDi reports that fewer than 10% of people living with Chagas disease know they are infected. These figures explain why the commercial opportunity remains diagnosis-constrained even though two established etiological drugs are available. [WHO, Apr 2026]; [DNDi, 2025] The market contains two distinct revenue pools. Antiparasitic therapy is concentrated in acute, congenital, reactivated, and early chronic infection, where treatment can clear the parasite and provide the greatest clinical benefit. The second pool is Chagas-attributable pharmacological management of chronic organ damage. WHO states that up to one-third of chronically infected people develop cardiac alterations and about one in ten develop digestive, neurological, or mixed complications. WHO's 2030 road map target of 75% antiparasitic-treatment coverage among the eligible population provides a clear policy catalyst, but execution depends on screening, referral, treatment completion, and medicine access. [WHO, Apr 2026] Chagas Disease Treatment Market Key Report Takeaways The segmentation below represents revenue, not patient prevalence. In particular, the acute-versus-chronic split should not be interpreted as the percentage of infected people in each disease phase. Drug shares are calculated within the antiparasitic-treatment segment, correcting the prior hierarchy error in which benznidazole and nifurtimox were incorrectly made to sum to the entire market. Segment Subsegment 2025 Share 2025 Value CAGR Disease Phase Acute Chagas Disease 22.0% USD 114.40 million 6.8% Chronic Chagas Disease 78.0% USD 405.60 million 8.3% Treatment Type Antiparasitic Treatment 64.0% USD 332.80 million 8.4% Chagas-Attributable Symptomatic Pharmacotherapy 36.0% USD 187.20 million 7.2% Antiparasitic Drug* Benznidazole 68.0% USD 226.30 million 7.7% Nifurtimox 32.0% USD 106.50 million 8.6% End User Hospitals 45.0% USD 234.00 million 7.6% Ambulatory/Home-Based Treatment 26.0% USD 135.20 million 8.6% Specialty Clinics 21.0% USD 109.20 million 8.3% Others 8.0% USD 41.60 million 7.4% Region Latin America 64.0% USD 332.80 million 7.7% North America 16.0% USD 83.20 million 8.6% Europe 10.0% USD 52.00 million 8.2% Asia-Pacific 6.0% USD 31.20 million 8.9% Middle East & Africa 4.0% USD 20.80 million 7.5% Benznidazole and nifurtimox shares are within the USD 332.80 million antiparasitic-treatment segment, not the USD 520 million total market. Diagnosis Conversion Is the Primary Commercial Constraint Chagas treatment is unusual because epidemiological burden does not translate directly into prescriptions. Fewer than 10% of infected people are diagnosed, and WHO reports that national information systems capable of monitoring acute and chronic cases and active transmission routes exist in only six of the 44 countries that have reported Chagas disease. Weak surveillance reduces the visibility of eligible patients and complicates forecasting, procurement, referral, and follow-up. [DNDi, 2025]; [WHO, Apr 2026] The most commercially important access change is movement of diagnosis closer to primary care. In 2025, Colombia became the first country to recommend rapid diagnostic tests in national technical guidelines for Chagas disease, following validation work supported by the National Institute of Health and DNDi. DNDi reported in March 2026 that implementation research using rapid tests had also begun in Argentina and Guatemala. A simpler test-and-treat pathway can increase treatment starts without requiring a new medicine. [DNDi, Jun 2025]; [DNDi, Mar 2026] Maternal and family screening is another high-yield channel. WHO estimated in 2026 that about 2 million women aged 15-44 years live with T. cruzi infection worldwide and that congenital transmission occurs in roughly 3-5% of pregnancies involving infected women. Screening a mother can identify the woman, an exposed newborn, and other children or siblings who require testing. Treating girls and women before pregnancy can also prevent future congenital transmission. For suppliers and health systems, this makes antenatal, reproductive-health, blood-donor, transplant, and cardiomyopathy pathways important case-finding infrastructure rather than peripheral public-health activity. [WHO, Chagas Day 2026] Benznidazole and Nifurtimox Define Current Treatment Economics Benznidazole and nifurtimox remain the two established medicines that treat T. cruzi infection. WHO describes both as fully effective when used early in acute disease, including congenital infection, while effectiveness decreases as infection becomes longer-standing. In the United States, CDC recommends antiparasitic treatment for all acute or reactivated cases, chronic infection in children, and strongly recommends treatment for adults up to age 50 with chronic infection who do not have advanced cardiomyopathy. Decisions for older adults are individualized. [WHO, Apr 2026]; [CDC Clinical Care] Current U.S. regulatory status is commercially relevant. Benznidazole is FDA-approved for children aged 2-12 years under accelerated approval and remained on FDA's ongoing accelerated-approval list in August 2026. Lampit (nifurtimox) is approved from birth to younger than 18 years in patients weighing at least 2.5 kg and converted from accelerated to traditional approval in June 2023. CDC lists approximately 60-day oral regimens for both products. Adult treatment in the United States is therefore largely based on physician-directed off-label use. [FDA Benznidazole, Aug 2026]; [FDA Lampit]; [CDC Clinical Care] Tolerability limits penetration in asymptomatic adults. WHO reports adverse reactions in up to 40% of treated adults, with greater frequency and severity at older ages. The landmark BENEFIT trial in 2,854 patients with established Chagas cardiomyopathy showed that benznidazole significantly reduced parasite detection but did not significantly reduce major cardiac clinical deterioration over follow-up. This finding supports a commercially important distinction: the strongest etiological-treatment opportunity lies before advanced irreversible organ damage, while established cardiomyopathy creates continuing pharmaceutical use for heart failure, anticoagulation, and rhythm-related management but not a proven opportunity to reverse disease with antiparasitic therapy. [WHO, Apr 2026]; [BENEFIT Trial] Access economics also differ sharply by geography. WHO makes donated nifurtimox available to national programmes and supports paediatric benznidazole donation, while benznidazole can also be obtained through no-profit channels. These mechanisms expand treatment availability but constrain price-based revenue growth in endemic markets. Market expansion therefore depends more on finding eligible patients, completing therapy, and improving the treatment profile than on raising prices for legacy drugs. [WHO, Apr 2026] Shorter Regimens and Novel Therapies Are the Main Pipeline Catalysts The most near-term development is regimen simplification rather than replacement of standard therapy. NuestroBen is a Phase III randomized multicentre study comparing two- and four-week benznidazole regimens with the standard eight-week regimen in adults with chronic indeterminate disease or mild cardiac progression. The study was expanded to 540 participants across Argentina and Bolivia. DNDi's March 2026 update expects recruitment to finish in the second quarter of 2027 and main results toward the end of 2028. If shorter regimens preserve efficacy, they could reduce exposure to adverse events, improve completion, and lower monitoring burden. [BMJ Open, 2025]; [DNDi, Mar 2026] Treatment-response biomarkers are being developed in parallel. DNDi continues work with the MultiCruzi platform and other biomarker approaches because conventional serology can remain positive for years after successful therapy. A validated earlier marker of treatment response would improve clinical decision-making and could shorten development timelines for new therapies. [DNDi, Mar 2026]; [DNDi Chagas Facts] Novartis is conducting a recruiting Phase II proof-of-concept trial of oral LXE408 in 130 adults aged 18-60 with chronic Chagas disease without severe organ dysfunction. The study compares LXE408 with benznidazole and placebo and was last updated by Novartis on August 19, 2026. This directly targets the large chronic population in which a better-tolerated adult therapy could materially change treatment practice. [Novartis, Aug 2026] AN2 Therapeutics is developing oral AN2-502998, a CPSF3 inhibitor, with DNDi. In June 2026 the company reported favourable Phase I safety and tolerability in healthy volunteers and parasite elimination after a 28-day course in all treated nonhuman primates in a naturally acquired chronic-infection model. The animal result is not evidence of human efficacy. AN2's August 11, 2026 update stated that Phase II initiation in chronic Chagas disease was planned by year-end. [AN2, Jun 2026]; [AN2, Aug 2026] Pipeline attrition remains important to forecast risk. DNDi reported that DNDI-6148 clinical development remains on hold, while fexinidazole was not advanced because it did not demonstrate the expected efficacy against Chagas disease. These setbacks reinforce that an 8.0% market CAGR should not assume every investigational programme succeeds. [DNDi, Mar 2026] Regional Commercialization Is Split Between Volume and Revenue Opportunity Latin America represents an estimated 64% of 2025 market revenue and remains the centre of treated-patient volume. Chagas disease is endemic in 21 continental Latin American countries, and the region contains the deepest clinical experience, public procurement infrastructure, benznidazole manufacturing, and most disease-specific trial sites. Colombia's rapid-test adoption and the Argentina-Bolivia NuestroBen programme show how diagnosis and treatment innovation can translate into greater volume. The limiting factor is unit economics: government purchasing, donation, and no-profit access reduce the revenue captured per treatment course. [WHO, Apr 2026]; [DNDi, Jun 2025] North America accounts for an estimated 16% of 2025 revenue but offers higher commercial value per treated patient. A May 2026 CDC Emerging Infectious Diseases commentary cited an estimate of about 288,000 people with Chagas disease in the United States, most infected outside the country. Commercial availability of benznidazole and nifurtimox, specialist infectious-disease and cardiology care, and active clinical research support market development. The opportunity remains underpenetrated because diagnosis is concentrated in at-risk migrant populations and adult use is outside current paediatric FDA labels. [CDC EID, May 2026]; [CDC Clinical Care] Europe represents an estimated 10% of revenue and is primarily a migrant-health, congenital-risk, blood-safety, and transplant market. WHO states that the European Union recommends Chagas screening of blood donors and screening of organ donors and recipients, with implementation in several countries. Asia-Pacific, estimated at 6%, remains a smaller specialist market; WHO reports universal blood-donor and pre-transplant screening in Japan and risk-based approaches in Australia. Middle East & Africa, at an estimated 4%, is primarily an imported-case and specialist-referral market rather than a major near-term revenue pool. [WHO, Apr 2026] Competitive Positioning Depends on Access, Supply Security, and Adult Pipeline Differentiation The established market is concentrated, but conventional brand competition is limited. Bayer's position is built around nifurtimox/Lampit, paediatric usability, manufacturing, and global access. WHO and Bayer renewed their neglected-tropical-disease collaboration for 2025-2030; the agreement covers 18 million donated tablets and vials valued at USD 15.5 million across Chagas disease, sleeping sickness, and taeniasis/cysticercosis, plus USD 9.45 million in programme support. The quantities are multi-disease and should not be attributed entirely to Chagas. [WHO-Bayer, Nov 2025] The benznidazole ecosystem includes Insud Pharma/Chemo Research, Exeltis, Mundo Sano, Elea Phoenix, and Brazil's state-owned LAFEPE. Exeltis distributes FDA-approved Benznidazole Tablets in the United States and operates the FastAccess patient-support programme, which includes assistance for eligible uninsured and commercially insured patients. Elea markets Abarax in 50 mg and 100 mg strengths and co-sponsors NuestroBen with DNDi. LAFEPE continues to manufacture 12.5 mg and 100 mg benznidazole for Brazilian public-sector requirements; 2025 procurement documentation explicitly lists ongoing production for Ministry of Health supply. [Exeltis FastAccess]; [Elea Abarax]; [LAFEPE, 2025] Pipeline competition is more differentiated. Novartis is targeting chronic adults through LXE408, while AN2 is pursuing a potential shorter-course novel mechanism with AN2-502998. DNDi should be viewed as an R&D and access ecosystem partner rather than a pharmaceutical competitor: its role spans shorter-regimen development, biomarkers, rapid diagnosis, clinical networks, and collaboration with both established manufacturers and emerging developers. For a CEO assessing entry or partnership, the durable competitive advantage is therefore not simply ownership of a molecule; it is the ability to combine evidence generation, reliable supply, diagnosis conversion, affordability, and treatment completion. [Novartis, Aug 2026]; [AN2, Aug 2026]; [DNDi, Mar 2026] Chagas Disease Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 520 Million Revenue Forecast in 2032 USD 890 Million Overall Growth Rate CAGR of 8.0% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Disease Phase, By Treatment Type, By Antiparasitic Drug, By End User, By Geography By Disease Phase Acute Chagas Disease, Chronic Chagas Disease By Treatment Type Antiparasitic Treatment, Chagas-Attributable Symptomatic Pharmacotherapy By Antiparasitic Drug Benznidazole, Nifurtimox By End User Hospitals, Ambulatory/Home-Based Treatment, Specialty Clinics, Others By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Brazil, Argentina, Bolivia, Colombia, Guatemala, Mexico, Spain, Italy, Japan, Australia, and Other Relevant Endemic and Non-Endemic Markets Market Drivers Low diagnosis rates creating substantial treatment-conversion potential; expansion of rapid diagnostic testing and decentralized test-and-treat pathways; rising maternal, congenital, and family screening; broader treatment of eligible chronic patients; development of shorter benznidazole regimens and novel antiparasitic therapies Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the major opportunities available in this market? A1. The largest opportunity is converting the substantial undiagnosed population into treated patients through simpler screening and referral pathways. Maternal screening, rapid diagnostics, congenital case finding and earlier treatment of chronic infection could expand the treatment-eligible population considerably. Q2. How are changing clinical needs influencing demand in the industry? A2. Clinical focus is shifting toward earlier treatment, better tolerability and higher treatment-completion rates. This is increasing interest in shorter benznidazole regimens and novel therapies that could provide effective parasite clearance with less treatment burden than current 60-day courses. Q3. What emerging technologies could impact future growth in the market? A3. Treatment-response biomarkers, rapid diagnostic tests and new antiparasitic mechanisms could materially change patient management. Programs involving LXE408 and AN2-502998 are particularly important because they target chronic adult patients who represent a large but undertreated population. Q4. How is demand changing across different regions in the industry? A4. Latin America remains the largest treatment-volume region because most endemic transmission occurs there, although public procurement and donation programs constrain revenue per patient. North America and Europe offer smaller patient pools but potentially higher commercial value through specialist treatment of migrant and congenital-risk populations. Q5. What factors could limit future market growth? A5. Underdiagnosis remains the largest constraint, with fewer than 10% of infected people estimated to know their status. Adverse effects from established therapies, limited adult regulatory labeling in the United States and pipeline failures can also restrict treatment expansion. Q6. What factors should businesses consider before entering this industry? A6. Companies need to consider diagnostic access, treatment completion, affordability, public procurement and reliable medicine supply rather than focusing only on drug pricing. A successful strategy will also require evidence in chronic adults and partnerships with public-health networks because many patients are reached through screening and access programs rather than conventional commercial channels. Table of Contents - Global Chagas Disease Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Disease Phase, Treatment Type, Antiparasitic Drug, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Disease Phase, Treatment Type, Antiparasitic Drug, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Disease Phase, Treatment Type, Antiparasitic Drug, and End User Investment Opportunities in the Chagas Disease Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Antiparasitic Treatment, Chagas-Attributable Symptomatic Pharmacotherapy, Shorter Treatment Regimens, Rapid Diagnostic Pathways, Maternal and Family Screening, and Novel Therapies Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Chagas Disease Treatment in Parasite Eradication, Chronic Disease Management, Diagnosis Conversion, and Treatment Access Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Clinical, Diagnostic, and Access Factors Role of Rapid Diagnostic Testing, Decentralized Test-and-Treat Pathways, Maternal Screening, Family Screening, Blood-Donor Screening, and Transplant Screening in Market Expansion Role of Treatment Completion, Tolerability, Supply Security, and Novel Antiparasitic Development in Market Development Global Chagas Disease Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Phase: Acute Chagas Disease Chronic Chagas Disease Market Analysis by Treatment Type: Antiparasitic Treatment Chagas-Attributable Symptomatic Pharmacotherapy Market Analysis by Antiparasitic Drug: Benznidazole Nifurtimox Market Analysis by End User: Hospitals Ambulatory/Home-Based Treatment Specialty Clinics Others Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Chagas Disease Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Phase, Treatment Type, Antiparasitic Drug, and End User Country-Level Breakdown: United States Canada Mexico Europe Chagas Disease Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Phase, Treatment Type, Antiparasitic Drug, and End User Country-Level Breakdown: Spain Italy Rest of Europe Asia Pacific Chagas Disease Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Phase, Treatment Type, Antiparasitic Drug, and End User Country-Level Breakdown: Japan Australia Rest of Asia-Pacific Latin America Chagas Disease Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Phase, Treatment Type, Antiparasitic Drug, and End User Country-Level Breakdown: Brazil Argentina Bolivia Colombia Guatemala Mexico Rest of Latin America Middle East & Africa Chagas Disease Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Phase, Treatment Type, Antiparasitic Drug, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates (UAE) Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Bayer AG Insud Pharma Exeltis Mundo Sano Elea Phoenix LAFEPE Novartis AG AN2 Therapeutics, Inc. Drugs for Neglected Diseases initiative Chemo Research Eisai Co., Ltd. Sanofi GlaxoSmithKline plc Takeda Pharmaceutical Company Limited Competitive Landscape and Strategic Insights Benchmarking Based on Treatment Portfolio, Regulatory Positioning, Product Availability, Global Access Programs, Manufacturing Capability, Clinical Development, Distribution Network, and Regional Presence Supplier Qualification and Access Capability Analysis Antiparasitic Treatment Positioning Chagas-Attributable Symptomatic Pharmacotherapy Competitiveness Shorter-Regimen and Novel Therapy Pipeline Strategy Analysis Rapid Diagnostic Testing, Diagnosis Conversion, Maternal Screening, Family Screening, and Treatment Completion Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Disease Phase, Treatment Type, Antiparasitic Drug, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory, Access, Diagnosis Conversion, and Treatment Completion Analysis Pipeline and Treatment Innovation Trends Across Benznidazole, Nifurtimox, Shorter-Regimen Development, Biomarker Development, and Novel Antiparasitic Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Disease Phase, Treatment Type, Antiparasitic Drug, and End User (2025 vs. 2032) Global Chagas Disease Treatment Ecosystem and Value Chain Analysis